MedTrace Logo

Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor

NCT03907670 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2019-09-30

No results posted yet for this study

Summary

The aim of the study is to assesse the levels of various biomarkers, specifically interleukin (IL)-6, platelet-derived microparticles (PDMPs), 11, 12 soluble vascular cell adhesion molecule 1 (sVCAM-1), transforming growth factor (TGF) β1, and sCTLA-4, in TKI-treated patients with CML.

To measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML..

Conditions

  • Chronic Phase Chronic Myelogenous Leukemia

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2020-10-01
Completion
2021-10-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03907670 on ClinicalTrials.gov